Corvus Pharmaceuticals, Inc. (CRVS) Tops Q2 EPS by 3c
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Join SI Premium – FREE
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13).
For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
- JPMorgan Starts Multi Commodity Exchange of India Ltd (MCX:IN) at Underweight
- Rocket Lab launches U.S. Space Force mission in record 16 hours
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
